Genes & Chromosomes

A Stony Brook-based company believes it has the guts to tackle the SAT cheating scandal - and the genes too. James Hayward, president and CEO of Applied DNA Sciences, spoke before the New...

What keeps San Diego County's biotech cluster churning? Some industry observers say that success is simply in its DNA. Anchored by gene-sequencing giants Life Technologies Corp. and Illumina Inc., whose powerful DNA analysis...

-- Test Associated with Changes in Treatment Management in 65% of Patients with Difficult-to-Diagnose Cancers -- REDWOOD CITY, Calif. -- Pathwork Diagnostics, Inc., a pioneer in creating genomics-based diagnostics in oncology utilizing their...

Pharmacogenetic Patents Have the Potential to Extend Drug Candidate's Potential Commercial Exclusivity Period If Regulatory Approval Obtained BROOMFIELD, Colo. -- ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company developing genetically targeted therapies for cardiovascular...

DUBLIN -- Research and Markets (http://www.researchandmarkets.com/research/2c0db2/market_and_product) has announced the addition of the "Market and Product Forecasts: Top 20 Oncology Therapy Brands - The value of the top 20 decreases as the oncology market...

SHEFFIELD, England -- Simcyp Limited, the leader in modelling and simulation of drug-drug interactions in virtual human populations, today announces it has extended its animal models to include a virtual mouse. Laboratory mice...

MADISON, Wis. -- Promega announces the beta launch of the online gene exploration tool Find My Gene([TM]). Find My Gene integrates a number of robust functionalities to help researchers better understand their gene's...

Developing therapeutics using novel biology to selectively activate genes CAMBRIDGE, Mass. -- RaNA Therapeutics, Inc. today announced it has completed a $20.7 million round of financing co-led by Atlas Venture, SR One, and...

Cold adapted and heat-labile unique Enzymes that Improve Molecular Biology TROMSO, Norway -- ArcticZymes AS announced today the formation of ArcticZymes Inc. a wholly owned subsidiary located in Plymouth Meeting, PA. The Company...

SAN DIEGO -- Illumina, Inc. (NASDAQ:ILMN) today announced that it will issue results for fourth quarter and fiscal year 2011 following the close of market on Tuesday, January 31, 2012. On the same...

CAMBRIDGE, Mass. -- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has filed a patent infringement lawsuit against Tekmira Pharmaceuticals Corporation in the U.S. District Court of...

SOUTH SAN FRANCISCO, Calif. & ST. LOUIS -- MOgene, LC, a leading genomics service provider located in St. Louis, is implementing Fluidigm Access Array[TM] sample preparation technology for its targeted resequencing customers. The...

DUBLIN -- Research and Markets(http://www.researchandmarkets.com/research/d990a7/product_profiles) has announced the addition of the "Product Profiles: Targeted Cancer Therapies - Trend towards personalized medicine will lead to market fragmentation" report to their offering. The targeted therapies...

BioTrends Research Group, LLC has released findings from the LaunchTrends([R]): Xalkori report, which is tracking the launch of this new targeted therapy. The study finds that Pfizer's Xalkori (crizotinib), which is indicated for...

New Genome Biology publication validates potential for cost-effective clinical sequencing with integrated RainDance and Illumina MiSeq[TM] workflow LEXINGTON, Mass. -- RainDance Technologies, Inc., the Digital Biology[TM] Company, today announced the publication of data...

The Montreal Heart Institute will work with GnuBIO to develop a genetic sudden cardiac death screening panel in order to predict risk in patients CAMBRIDGE, Mass. -- GnuBIO, Inc. (GnuBIO), www.gnubio.com a pioneer...

Groundbreaking Cleveland Clinic Study Published in "Microvascular Research" ALPHARETTA, Ga. -- SANUWAVE Health, Inc. (OTCBB: SNWV), an emerging medical technology company focused on the development and commercialization of noninvasive, biological response activating devices...

Fifth Partnership Will Help Translate Cancer Genomic Science to Clinical Results CAMBRIDGE, Mass. -- Foundation Medicine, Inc., a molecular information company that brings comprehensive cancer genome analysis to routine clinical care, today announced...

- Partnership Includes US Profit Share and Co-Promotion Option for Epizyme - CAMBRIDGE, Mass. -- Epizyme, Inc., a company leading the discovery and development of personalized therapeutics for genetically-defined cancer patients, today announced...